JPWO2022234853A1 - - Google Patents

Info

Publication number
JPWO2022234853A1
JPWO2022234853A1 JP2023518700A JP2023518700A JPWO2022234853A1 JP WO2022234853 A1 JPWO2022234853 A1 JP WO2022234853A1 JP 2023518700 A JP2023518700 A JP 2023518700A JP 2023518700 A JP2023518700 A JP 2023518700A JP WO2022234853 A1 JPWO2022234853 A1 JP WO2022234853A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023518700A
Other languages
Japanese (ja)
Other versions
JPWO2022234853A5 (https=
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2022234853A1 publication Critical patent/JPWO2022234853A1/ja
Publication of JPWO2022234853A5 publication Critical patent/JPWO2022234853A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023518700A 2021-05-07 2022-05-06 Pending JPWO2022234853A1 (https=)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021079012 2021-05-07
PCT/JP2022/019544 WO2022234853A1 (ja) 2021-05-07 2022-05-06 Hrasおよびnrasに対して選択的なkras阻害作用を有する環状化合物

Publications (2)

Publication Number Publication Date
JPWO2022234853A1 true JPWO2022234853A1 (https=) 2022-11-10
JPWO2022234853A5 JPWO2022234853A5 (https=) 2025-04-24

Family

ID=83932768

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023518700A Pending JPWO2022234853A1 (https=) 2021-05-07 2022-05-06

Country Status (17)

Country Link
US (1) US20240158446A1 (https=)
EP (1) EP4309741A4 (https=)
JP (1) JPWO2022234853A1 (https=)
KR (1) KR20240005777A (https=)
CN (1) CN117279933A (https=)
AR (1) AR125796A1 (https=)
AU (1) AU2022268781A1 (https=)
BR (1) BR112023022755A2 (https=)
CA (1) CA3218182A1 (https=)
CL (1) CL2023003137A1 (https=)
CO (1) CO2023014807A2 (https=)
CR (1) CR20230572A (https=)
IL (1) IL307605A (https=)
MX (1) MX2023013139A (https=)
PE (1) PE20250071A1 (https=)
TW (1) TW202309063A (https=)
WO (1) WO2022234853A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202446781A (zh) 2011-12-28 2024-12-01 日商中外製藥股份有限公司 胜肽化合物之製造方法
EP4166664A1 (en) 2015-03-13 2023-04-19 Chugai Seiyaku Kabushiki Kaisha Modified aminoacyl-trna synthetase and use thereof
JP7187323B2 (ja) 2017-01-31 2022-12-12 中外製薬株式会社 無細胞翻訳系におけるペプチドの合成方法
KR20250007021A (ko) 2017-06-09 2025-01-13 추가이 세이야쿠 가부시키가이샤 N-치환 아미노산을 포함하는 펩타이드의 합성 방법
EP3878836B1 (en) 2018-11-07 2025-07-23 Chugai Seiyaku Kabushiki Kaisha O-substituted serine derivative production method
EP4056580A4 (en) 2019-11-07 2023-12-06 Chugai Seiyaku Kabushiki Kaisha METHOD FOR PRODUCING A PEPTIDE COMPOUND COMPRISING A STERICALLY HINDERED AMINO ACID
BR112022007535A2 (pt) 2019-11-07 2022-07-12 Chugai Pharmaceutical Co Ltd Composto peptídico cíclico tendo ação inibitória de kras
US12312379B2 (en) 2021-05-07 2025-05-27 Chugai Seiyaku Kabushiki Kaisha Methods for producing cyclic compounds comprising N-substituted amino acid residues
JP7823181B2 (ja) * 2022-05-06 2026-03-03 中外製薬株式会社 Hrasおよびnrasに対して選択的なkras阻害作用を有する環状化合物
CN115385867A (zh) * 2022-09-19 2022-11-25 安徽普利药业有限公司 一种氨基酸及其类似物的成环反应与开环方法
TW202430537A (zh) * 2022-10-20 2024-08-01 日商中外製藥股份有限公司 環狀胜肽的結晶的製造方法
EP4603105A1 (en) * 2022-11-09 2025-08-20 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing cyclic compound having selective kras inhibitory effect against hras and nras
CN120659773A (zh) * 2022-11-09 2025-09-16 锐新医药公司 化合物、复合物以及其制备方法和用途
WO2024101386A1 (ja) * 2022-11-09 2024-05-16 中外製薬株式会社 Hrasおよびnrasに対して選択的なkras阻害作用を有する環状化合物
WO2024195801A1 (ja) 2023-03-20 2024-09-26 中外製薬株式会社 環状ペプチドの共結晶の製造方法
TW202506168A (zh) 2023-04-19 2025-02-16 日商中外製藥股份有限公司 包含環狀胜肽化合物及界面活性劑之組合物
CN120936619A (zh) 2023-04-20 2025-11-11 中外制药株式会社 用于生产环肽化合物的方法
CN116655766B (zh) * 2023-04-23 2023-12-12 山东第一医科大学(山东省医学科学院) 一种订书肽及其制备方法和应用
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025162428A1 (en) * 2024-01-29 2025-08-07 Syneron Technology Co. Ltd. Cyclic peptide compounds and compositions as ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
CN118324664B (zh) * 2024-03-14 2026-04-07 四川鸿日医药科技有限公司 一种丝氨酸衍生物的制备方法
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ras抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026004834A1 (ja) * 2024-06-25 2026-01-02 中外製薬株式会社 固体分散体、及びそれを含む組成物
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026009920A1 (ja) * 2024-07-03 2026-01-08 中外製薬株式会社 環状ペプチドの精製法及び製造法
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2586411T3 (es) 2011-03-04 2016-10-14 New York University Macrociclos sustitutos de enlace de hidrógeno como moduladores de Ras
TW202446781A (zh) 2011-12-28 2024-12-01 日商中外製藥股份有限公司 胜肽化合物之製造方法
WO2015179438A1 (en) * 2014-05-20 2015-11-26 Ohio State Innovation Foundation Small molecule rac or rho inhibitors
US10954287B2 (en) * 2016-04-15 2021-03-23 Ra Pharmaceuticals, Inc. Ras binding peptides and methods of use
CN110869544B (zh) 2017-06-09 2024-03-08 中外制药株式会社 膜透过性高的环状肽化合物及包含其的文库
KR20250007021A (ko) * 2017-06-09 2025-01-13 추가이 세이야쿠 가부시키가이샤 N-치환 아미노산을 포함하는 펩타이드의 합성 방법
WO2020122182A1 (ja) * 2018-12-12 2020-06-18 中外製薬株式会社 分子内水素結合可能な官能基を有するアミノ酸とそれらのアミノ酸を含むペプチド化合物、およびそれらの製造方法
BR112022007535A2 (pt) * 2019-11-07 2022-07-12 Chugai Pharmaceutical Co Ltd Composto peptídico cíclico tendo ação inibitória de kras

Also Published As

Publication number Publication date
CL2023003137A1 (es) 2024-06-14
IL307605A (en) 2023-12-01
PE20250071A1 (es) 2025-01-13
CR20230572A (es) 2024-01-25
CA3218182A1 (en) 2022-11-10
MX2023013139A (es) 2023-11-28
AR125796A1 (es) 2023-08-16
TW202309063A (zh) 2023-03-01
CN117279933A (zh) 2023-12-22
US20240158446A1 (en) 2024-05-16
EP4309741A1 (en) 2024-01-24
WO2022234853A1 (ja) 2022-11-10
KR20240005777A (ko) 2024-01-12
EP4309741A4 (en) 2025-05-14
BR112023022755A2 (pt) 2024-01-02
CO2023014807A2 (es) 2023-11-20
AU2022268781A1 (en) 2023-12-21

Similar Documents

Publication Publication Date Title
JPWO2022234853A1 (https=)
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011610A2 (https=)
BR112023011539A2 (https=)
BR112023008976A2 (https=)
BR102021010467A2 (https=)
BR102021009555A2 (https=)
BR102021009475A2 (https=)
BR102021007978A2 (https=)
BR102021004425A2 (https=)
BR112023008622A2 (https=)
BR102020022457A2 (https=)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250416

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250416